Investor Overview · 2026
MRR
Brands
Group
Recurring Revenue Infrastructure for Regulated Markets
Market Opportunity
A $300B+
Regulated Market.
Underbuilt Rails.
The addressable market across telehealth, subscription health, compounding pharmacy, and regulated payments is massive — and still largely running on fragmented, single-point infrastructure.
$286B
Global Telehealth Market by 2030
Growing at ~18% CAGR from $87B in 2023. Virtual-first care is now the default expectation — not a pandemic anomaly. Infrastructure operators capture the margin the brands leave behind.
$100B+
U.S. Weight Management & Metabolic Health
GLP-1 demand has permanently expanded the clinical weight loss market. Physician-supervised programs with pharmacy fulfillment are the highest-margin segment — and the fastest growing.
$10B+
U.S. Compounding Pharmacy Market
503A compounding sits at the intersection of clinical demand and regulatory access. Operators with established pharmacy relationships capture embedded margin most platforms never see.
The market is enormous. The infrastructure to serve it at scale barely exists.
Most operators are cobbling together point solutions across billing, compliance, prescribing, and fulfillment. MRR is building the stack they all need.
Market Timing
The Window
Is Open.
Five structural forces are converging right now — creating a category-defining window for an infrastructure aggregator operating across regulated health markets.
→
The GLP-1 revolution has permanently expanded clinical demand
Weight loss, metabolic health, and physician-supervised programs are mainstream consumer expectations. The infrastructure to deliver them compliantly — at scale — is the bottleneck.
→
Post-COVID telehealth normalization is permanent
Consumers now expect virtual care as a default. The addressable patient base for telehealth-delivered clinical programs has expanded by orders of magnitude since 2020.
→
Single-point telehealth brands are showing structural cracks
Direct-to-consumer telehealth companies face CAC inflation, commoditization, and margin compression. The advantage now belongs to infrastructure operators — not brand operators.
→
Regulated recurring revenue is a premium asset class
Accredited investors and PE firms are actively seeking platforms with compliance infrastructure, recurring cash flow, and structural moats in regulated verticals. The category commands premium multiples.
→
Compounding pharmacy access creates a near-term margin window
FDA compounding access for GLP-1 and related compounds represents a significant near-term margin opportunity for operators with established 503A pharmacy relationships already in place.
This isn't a future trend. It's already in motion — and the infrastructure window is open now.
The operators building compliant recurring revenue infrastructure in regulated health markets today are positioning for exits in the 12–20x+ range. The window favors early movers.
Platform Architecture
Three
Infrastructure
Layers.
One compounding platform. Every layer stacks revenue, compounds margin, and deepens switching costs — simultaneously.
01
Membership & Licensing Rails
Front-end acquisition and monetization. DTC, CPG, and health brands plug into white-label infrastructure with embedded payment rails and physician/pharmacy connectivity.
02
Telehealth & Clinical Rails
Fully managed telehealth for brands, physicians, fitness professionals, and affiliates. EMR, prescribing access, compliance management, and recurring subscription infrastructure.
03
Payments & Pharmacy Rails
Regulated processing, 503A compounding, fulfillment, and a national prescribing network. The infrastructure moat competitors cannot replicate quickly.
Revenue Stacking
Multiple streams per customer across all three layers
High Switching Costs
Compliance infrastructure creates deep operational dependency
Vertical Defensibility
Owning all layers limits competitive displacement at scale
Revenue Flow
Every Layer
Generates Revenue.
Every Layer Compounds.
Brand / Creator / CPG Operator
Brings patients, customers, audience
↓
Freedom Industries / Mission One
Membership rails, licensing, front-end billing
↓
Freedom MD Telehealth Platform
EMR, prescribing, compliance, clinical programs
↓
Precision Physicians Network
National prescribing coverage & oversight
↓
Precision Pharmacy + Payments
Fulfillment, billing control, margin capture
Recurring revenue at every node
Membership, platform, pharmacy, and payment streams stack per active customer. Revenue compounds without adding headcount.
Embedded margin at the infrastructure layer
Pharmacy fulfillment and payment spread generate margin that competitors never see — because they don't own the rails.
Structural switching costs
Once a brand is embedded across compliance, billing, and fulfillment — leaving is operationally costly and clinically disruptive.
Portfolio Company — 01
Freedom Industries
/ Mission One
Membership & Licensing Platform — Front-End Acquisition Layer
Hosts DTC, CPG, and health brands on white-label membership infrastructure. Embeds payment rails and connects the operator's audience directly to the physician and pharmacy stack.
- DTC / CPG / health brand hosting on branded infrastructure
- White-label technology, billing, and member portal architecture
- Embedded payment rails with full subscription billing control
- 1,000,000+ active email subscribers — owned, warm audience
- Direct conduit to Freedom MD patient acquisition pipeline
Revenue Streams
- Membership fees
- Licensing fees
- Backend infrastructure fees
- Payment participation
- Subscription recurring revenue
The front door to the entire MRR ecosystem — and the origin of the patient acquisition flywheel.
Portfolio Company — 02
Freedom MD
Fully Managed Telehealth Platform — Clinical Monetization Layer
Enables brands, physicians, fitness professionals, influencers, and affiliates to deploy compliant telehealth programs — without building any clinical infrastructure themselves.
- Telehealth portal + EMR infrastructure
- Prescribing physician network access
- Compliance management & regulatory oversight (HIPAA, Legit Script)
- Prescription program integration with direct-to-patient fulfillment
- Recurring subscription management — MRR by design
Built For
- Brands & CPG companies
- Physicians & medical professionals
- Fitness professionals & coaches
- Influencers & affiliates
Revenue Streams
- Platform fees & operator revenue share
- Clinical program margin
- Subscription MRR per enrolled patient
The clinical monetization engine — scales without proportional cost increases.
Portfolio Company — 03
Precision Partners —
The Infrastructure
Backbone
01 · Precision Payments
Regulated Payment Rails
High-risk vertical specialization
- High-risk vertical processing
- Subscription billing control
- Revenue participation on volume
- Chargeback infrastructure
02 · Precision Pharmacy
Fulfillment & Distribution
503A compounding infrastructure
- 503A compounding relationships
- Script-to-ship integration
- Direct-to-patient distribution
- Embedded margin per prescription
03 · Precision Physicians
National Prescribing Network
Compliance-first clinical oversight
- National prescribing coverage
- Nationwide telehealth licensing
- Clinical protocol management
- Quality & compliance oversight
This is the regulated infrastructure moat.
Competitors can build a brand. They cannot rapidly replicate the rails — approvals, licensure, and network depth take years.
Competitive Advantage
Most Own
One Layer.
MRR Owns
the Rails.
01
Revenue per customer is compounded — not linear
Membership + clinical program + pharmacy margin + 2–4% payment spread + platform licensing. Multiple streams stack invisibly on a single patient relationship — without the patient noticing.
02
The moat is structural, not brand-based
Compliance rails are not copyable overnight. Pharmacy relationships require licensure and volume history. High-risk payment approvals take years. Physician network depth creates a prescribing volume barrier.
03
Infrastructure aggregators command category-leading multiples
Telehealth brands are commoditized. The valuation premium belongs to the operator that controls cash flow infrastructure at the layer beneath all of them.
Regulated infrastructure aggregation. The category commands a premium.
Higher multiples than single telehealth brands, DTC supplement companies, or pure SaaS platforms — because MRR sits at the revenue layer, not the brand layer.
Strategic Moat — Patient Acquisition
Near-Zero CAC.
1M Owned
Subscribers.
Most telehealth companies spend $300–$1,000+ to acquire every patient through paid media. Freedom MD acquires through a warm, owned audience — at near-zero marginal cost.
01
Freedom Industries email list — 1,000,000 active subscribers
Health and wellness aligned audience. Not cold traffic — these are existing customers and members with pre-established brand trust. No ad spend required to reach them.
02
Cross-sell is a warm conversation, not a cold ad
A subscriber who already purchases from Freedom Industries is pre-qualified for a Freedom MD clinical offer. The offer extends a relationship, not disrupts one.
03
Multiple owned channels compound the flywheel
Email, brand cross-promotion, content, community, and affiliate channels all feed the same patient pipeline — each additional channel reduces blended CAC further.
~$0 CAC
vs. $300–$1,000+ per patient for competitors running paid acquisition
Higher Margins
No acquisition cost means LTV flows directly to platform margin
Compounding Flywheel
As the list grows, the patient pipeline expands at zero incremental CAC
Revenue Model
One Patient.
Five Revenue
Streams.
A single patient relationship generates membership MRR, clinical MRR, pharmacy margin, payment spread, and platform fees — simultaneously and invisibly.
| Revenue Layer | Source | Type |
|---|
| Membership | $99 / month per member | MRR |
| Clinical Program | $150 / month per enrolled patient | MRR |
| Pharmacy Margin | Embedded per prescription filled | Embedded |
| Payment Spread | 2–4% on all transaction volume | % Revenue |
| Platform / Licensing | Operator infrastructure fee | Embedded |
Visible Per-Member MRR
$249+
Membership + clinical monthly
Plus Embedded Margin
Pharmacy
+ Payments
Captured at the infrastructure layer
Combined Result
High LTV ·
High Retention
Revenue compounds per member per month
Pro Forma · Freedom Industries → Freedom MD
$50M–$150M
From One List.
1,000,000 active subscribers. Converting 1–3% into Freedom MD patients at a $5,000 LTV produces the following lifetime revenue opportunity.
Even 1% conversion produces a $50M lifetime revenue opportunity.
1,000,000 subscribers · AOV $500 · Patient LTV $5,000 · Near-zero CAC
Conversion Benchmarks
1–3%
Is the Conservative
Case.
Healthcare email benchmarks consistently show conversion rates well above the 1–3% MRR projects — particularly for warm, existing-customer lists.
| Channel | Typical Conversion |
|---|
| Email → Health product purchase | 1–5% |
| Email → Telehealth consult | 2–6% |
| Webinar / education funnel | 3–10% |
| Existing customer cross-sell | 5–15% |
→
1M engaged, health-aligned subscribers
Not cold traffic. An audience that already buys health and wellness products is inherently qualified for a clinical offer.
→
Trust pre-established through existing brands
Freedom Industries subscribers have an existing purchase relationship. This is a warm cross-sell — not a cold acquisition.
→
No ad spend required — owned distribution
Direct-to-list conversion eliminates the $300–$1,000+ CAC that competitors absorb. Every patient converted is pure margin.
Expansion Revenue Per Patient
$5K LTV
Is the Floor.
Metabolic
Weight Loss & GLP-1
Physician-supervised protocols with pharmacy fulfillment. High retention, high LTV, strong compliance moat.
Hormonal
TRT & Peptide Protocols
Recurring monthly prescriptions with embedded pharmacy margin. Strong patient retention by design.
Longevity
Diagnostics & Supplements
Panels, IV therapy, and branded protocols — additive revenue on an already-acquired patient.
Multi-protocol patients represent $15,000–$30,000+ LTV · Zero incremental CAC
Investment Narrative
Three Companies.
One Compounding
Platform Asset.
Each portfolio company is independent. Together, they form a roll-up vehicle with infrastructure moat, owned patient acquisition, and compounding revenue rails across regulated markets.
Freedom Industries
Cash Flow Stability
Front-end acquisition, membership MRR, and licensing fees generate predictable baseline cash flow. The consumer-facing brand layer — and the origin of the 1M-subscriber patient flywheel.
Freedom MD
Platform Scalability
Telehealth infrastructure scales without proportional cost increases. Each new operator multiplies revenue across the clinical and pharmacy stack without rebuilding the core platform.
Precision Partners Group
Regulatory Moat
Payment approvals, pharmacy relationships, and national prescribing network represent years of regulatory capital — the infrastructure layer competitors cannot rapidly replicate.
DTC Supplement Brand
1–3x
Revenue multiple
Single Telehealth Brand
4–8x
EBITDA multiple
MRR Infrastructure Platform
12–20x+
Platform + infrastructure premium
MRR Brands Group
2026
Exit Thesis
The Infrastructure
Everyone Needs.
No One Else Controls.
MRR Brands Group is a regulated infrastructure platform aggregating recurring revenue across membership, telehealth, pharmacy, and payments — with owned patient acquisition at near-zero CAC and a $50M–$150M list monetization opportunity already in motion.
Owned Audience
1M+
Active subscribers
LTV Opportunity
$150M+
At 3% list conversion
Exit Multiple
12–20x+
Infrastructure aggregator
Revenue Streams
5+
Per patient relationship
MRR Brands Group · Investor Relations · 2026